Viswanathan Ravi

Average Profitability
<0.0001%
Insider Buys Quantity
12
Insider Buys Sum
$180.05M
Insider Sells Quantity
2
Insider Sells Sum
$132.15M

Insider Activity of Viswanathan Ravi

The largest purchase of all time was on 2018-09-07 and amounted to 30000000 shares of Adaptimmune Therapeutics plc for $50M.

The largest sale of all time was on 2017-11-20 and amounted to 5641032 shares of Appian Corporation for $109.94M.

Biography of Viswanathan Ravi

No biography is available at this moment.

2018-09-07PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
30M
4.8721%
$1.67$50M-57.66%
2018-03-27PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
12M
2.1988%
$1.92$23M-12.28%
2018-03-26PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
1.14M
0.2007%
$1.90$2.18M-14.01%
2018-03-23PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
588,180
0.1062%
$1.95$1.14M-12.52%
2018-03-22PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
1.74M
0.308%
$1.90$3.31M-12.12%
2018-03-21PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
209,688
0.0355%
$1.81$379,640-10.61%
2017-11-27SaleAppian Corporation
APPN
10 percent owner
1.14M
2.1156%
$19.49$22.2M+42.78%
2017-11-20SaleAppian Corporation
APPN
10 percent owner
5.64M
11.2735%
$19.49$109.94M+53.66%
2017-10-10PurchaseRhythm Pharmaceuticals, Inc.
RYTM
10 percent owner
550,000
1.3734%
$17.00$9.35M+9.57%
2017-07-03PurchaseMersana Therapeutics, Inc.
MRSN
10 percent owner
2M
9.7597%
$15.00$30M+20.77%
2017-03-27PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
25.74M
5.5147%
$0.70$18.02M+55.36%
2016-07-18PurchaseArdelyx, Inc.
ARDX
10 percent owner
3.05M
5.9523%
$8.73$26.67M+25.38%
2016-01-13PurchaseArdelyx, Inc.
ARDX
10 percent owner
1M
3.0335%
$10.00$10M+4.47%
2015-10-06PurchaseSynlogic, Inc.
SYBX
10 percent owner
857,142
4.1031%
$7.00$6M-36.97%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.